Deciphering the Multifaceted Immune Landscape of Unresectable Primary Liver Cancer to Predict Immunotherapy Response.

ABSTRACT: Immunotherapies employing PD-1/PD-L1 immune checkpoint inhibitors (ICIs) are vital for primary liver cancer (PLC), but response rates remain unsatisfying. Accurate differentiation of responders from non-responders to immunotherapy is imperative. Here, single-cell-scaled mass cytometry analysis on sequential peripheral blood mononuclear cells (PBMCs) from ICI-treated PLC patients is conducted, and tissue residence of immune subpopulations is assessed via multiplex immunohistochemistry. In the discovery cohort (n = 24), responders have lower baseline B cell and HLA-DR⁺CD8⁺T cell, and higher CD14⁺CD16^- classical monocyte (CM) proportions. CMs decrease more in responders PBMCs, while HLA-DR⁺CD8⁺T cells conformably amplify after

SUBMITTER: Xue J 

PROVIDER: S-EPMC11653612 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature